[{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Series C Financing","leadProduct":"GB-0669","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CAR T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.0700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.0700000000000001,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation"}]